Open AccessLeft ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib
Author(s) -
Imai Ryosuke,
Tomishima Yutaka
Publication year - 2020
Publication title -
respirology case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.304
H-Index - 9
ISSN - 2051-3380
DOI - 10.1002/rcr2.533
Subject(s) - nintedanib , medicine , idiopathic pulmonary fibrosis , cardiology , fibrosis , tyrosine kinase inhibitor , pulmonary fibrosis , lung , cancer
Nintedanib, a tyrosine kinase inhibitor, is approved for the treatment of idiopathic pulmonary fibrosis. We report a case of left ventricular dysfunction in a patient with idiopathic pulmonary fibrosis treated with nintedanib, which recovered after cessation of nintedanib. Nintedanib may induce left ventricular dysfunction, and early recognition is important since this condition is potentially reversible.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom